

Journal of Pharmaceutical and Applied

Chemistry



ISSN: 2357-0210

VOLUME 1, ISSUES2, 2015

www.egyptfuture.org/ojs/

Synthesis of Some New Fused Pyridines and Prediction their Biological Activity via PASS INET.

A. M. El-Sayed, H. Abdel-Ghany, A. A. Amer^{*} and A. M. Ahmed.

Chemistry Department, Faculty of Science, Sohag 82524, Egypt.

Received: 13 May 2015, Revised: 9 Jul. 2015, Accepted: 13 Jul. 2015. Published online: 1 Sep. 2015.

Abstract: A new series of fused heterocyclic compounds containing pyridine moieties were prepared via the reaction of 2amino-6-(methylthio)-4-phenylpyridine-3,5-dicarbonitrile with some halo reagents, active methylenes, acetic anhydride, phenylisothiocyanate, hydrazine hydrate or thioacetamide. Accompanied with Predictions of the activity spectra of some selected compounds using PASS INET.at Pa > 70%, showing high probability of Atherosclerosis treatment, Antineoplastic, DNA intercalator, Protein kinase inhibitor and Signal transduction pathways inhibitor.

Keywords: phase transfer catalysis; pyridine; pyrrole; pyrimidine; pyrrazole; fused pyridine; PASS INET.

1 Introduction

The considerable biological and medicinal activities of polyfunctionally substituted and condensed pyridines [1-7] have stimulated considerable recent research aimedat developing syntheses of these compounds. Pyrroles, pyrimidines and pyrazoles are well known examples of hetero-organic compounds associated with diverse biological and pharmacological properties. Pyrrole derivatives were reported as having important synthetic and activities[8,9] such biological as COX-1/COX-2 inhibitors[10] and cytotoxic activity against a variety of marine and human tumour models[11] .Pyrimidines are reported to have a broad spectrum of biological activities. Some are endowed with antitumor^[12], antiviral^[13], antiinflammatory[14], antipyretic[15], antimicrobial[16], and antifungal properties[17]. Pyrazole derivatives are synthetic targets of utmost importance in the pharmaceutical industry, since the pyrazole ring has been known as an important frame-work in a large number of drugs[18-21].


Considering the above very interesting pharmacological properties, we have now designed and synthesized some novel functionalized pyridines and their fused polycyclic ring systems, with important heterocycles such as pyrrole, pyrimidines and pyrazole with the hope to possess better biological activity.

2 Results and Discussions

The starting compound 2-amino-6-(methylthio)-4phenylpyridine3,5-dicarbonitrile **2** was prepared by the

Under phase transfer catalysis conditions (PTC) using dioxane as the organic phase, potassium carbonate as the solid phase and tetrabutylammonium bromide (TBAB) as a catalyst, compound 2 was allowed to react with diethyl malonate, ethyl cyanoacetate, phenacyl bromide or 2chloroacetamide to give ethyl 4-amino-6-cyano-2-hydroxy-7-(methylthio)-5-phenyl-1,8-naphthyridine-3-carboxylate 3,4-amino-2-hydroxy-7-(methylthio)-5-phenyl-1,8-naphthvridine-3,6-dicarbonitrile 4, 3-amino-2-benzoyl-6-(methylthio)-4-phenyl-1H-pyrrolo[2,3-b]-pyridine-5carbonitrile 5 or 3-amino-5-cyano-6-(methylthio)-4-phenyl-1H-pyrrolo[2,3-b]pyr-idine-2-carboxamide 6, respectively. Under similar PTC conditions, the reaction of compound 2 with ethyl bromoacetate in (1 : 1 or 1 : 2) molar ratio at room temperature afforded ethyl 2-(3-amino-5-cyano-2ethyloxycarbonyl-6-methylsulfanyl-4-phenyl-1H-pyrrolo-[2,3-b]- pyridin-1-yl)acetate 7, while, on heating gave ethyl 2-(5-cyano-2-ethyloxycarbonyl-6-methyl-sulfanyl-4phenyl-1H-pyrrolo[2,3-b]pyridin-3-ylamino) acetate (8), respectively (Scheme 1).

The IR spectra of compounds **3** and **4** showed new absorption bands at 3475 - 3396 cm⁻¹ corresponding to OH groups and at 1734 cm⁻¹ corresponding to C=Oester, in the case of compound **3**. The ¹H-NMR spectra of compounds **3** and **4** revealed new singlet signals at 4.20–4.00 ppm corresponding to OH groups and in the case of compound **3**, new quartet signal at 4.00–3.80 ppm corresponding to




 CH_2 ester group and a triplet signal at 1.20–1.00 ppm corresponding to CH_3 ester.

The IR spectra of compounds **5** and **6**showed new absorption bands at 3454–3213 cm⁻¹ corresponding to NH, NH₂ groups and at 1691–1680 cm⁻¹ corresponding to C=O groups. The ¹H-NMR spectra of compounds **5** and **6** revealed multiplet signals at 7.50–6.70 corresponding to (10 aromatic protons + NH₂ + NH) groups, , and new singlet signal at 6.20 ppm corresponding to CONH₂ group, in the case of compound **5**.


The IR spectra of compounds **7** and **8**showed new absorption bands at $1756 - 1750 \text{ cm}^{-1}$ corresponding to C=Oester groups. The mass spectrum of **7** showed the following fragmentation pattern m/e (rel. intensity %): 438 (M⁺, 58.51), 352 (M⁺+2 –CH₃COOEt, 51.07) and 279 (M⁺ –EtOOCCH₂COOEt, 100).While, the mass spectrum of **8** showed the following fragmentation pattern m/e (rel. intensity %): 438 (M⁺, 100), 365 (M⁺+1 –HCOOEt, 53.21) and 319 (M⁺–MeSCOOEt, 34.36).

Under similar reaction (PTC) conditions compound 2 was allowed to undergo cycloalkylation by heating with some halo reagents namely; 1,3-dibromopropane, 1,4dibromobutane, 2,3-dichloro-1,4-naphthoquinone or 2,3,5,6-tetrachloro-1,4-benzoquinone to give 6-(methylthio)-8-phenyl-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-7,9-dicarbonitrile 9, 7-(methylthio)-9-phenyl-2,3,4,5-tetrahydro-pyrido[1,2-a][1,3]diazepine-8,10dicarbonitrile 10, 4-methylsulfanyl-6,11-dioxo-2-phenyl-6,11-dihydronaphtho[2',3':4,5]imidazo[1,2-a]pyridine-1,3dicarbonitrile 11 or 7,8-dihydroxy-1-(methylthio)-6,9dioxo-3-phenyl-6,9-dihydropyrido[1,2-a]benzimid-azole-2,4-dicarbonitrile 12, respectively(Scheme 2). The IR spectra of compounds 9-12 showed the absence of absorption bands corresponding to NH₂ group while exhibit absorption bands at 2970-2947 cm⁻¹which revealed the presence of protons attached to SP³ carbons, in the case of compounds 9, 10 and at 1673–1624 cm⁻¹ corresponding to

C=O, in the case of compounds **11**, **12**. Also, the IR spectrum of compound **12** exhibit new absorption bands at 3736, 3444 cm⁻¹ corresponding to OH groups. The ¹H-NMR spectra of compounds **9-12** showed the absence of the signals corresponding to NH₂ group while revealed alicyclic protons signals at 4.40–1.60 ppm, in the case of compounds **9**, **10** and aromatic protons signals at 7.80–7.00 ppm, in the case of compound **11**. The ¹H-NMR spectrum of compound **12** showed new singlet signal at 3.80 ppm corresponding to 2 OH groups.



Cycloacetylation of compound 2 using acetic anhydride afforded 6-cyano-2-methyl-7-(methylthio)-5-phenylpyrido-[2,3-d]pyrimidin-4-yl acetate 13.Treatment of compound 2 with 2,5-dimethoxytetrahydrofuran yielded 2-(methylthio)-4-phenyl-6-(1H-pyrrol-1-yl)pyridine-3.5-dicarbonitrile 14. Under PTC reaction conditions compound 2 was allowed to react with phenylisothiocyanate to give 4-imino-7-(methylthio)-3,5-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyramid-ine-6-carbonitrile 15. Diazotization of compound 2with sodium nitrite and HCl/AcOH mixture gave 4-chloro-7-(methylthio)-5-phenylpyrido[2,3-d][1,2,3]triazine-6-carbonitrile 16. Oxidation of compound 2 with potassium permanganate in acetic acid afforded 2-amino-6-(methylsulfonyl)-4-phenylpyridine-3,5-dicarbonitrile 17. The sulfur-free compound 3,6-diamino-4-phenyl-1Hpyrazolo[3,4-b]pyridine-5-carbonitrile 18 was obtained by heating compound 2 with excess hydrazine hydrate. Also compound 2 was treated with thioacetamide in trifluoroacetic acid to give 2-methyl-7-methylsulfanyl-5-phenyl-4-(1-thioxoethylimino)-3,4-dihydropyrido-[2,3-d]pyrimidin-6-yl cyanide 19. The reaction mechanism for the formation of product 19 was suggested as shown in scheme 3.




The IR and ¹H-NMR spectra of compounds13-16 showed the absence of absorption bands corresponding to NH2 group. ¹H-NMR spectrum of compound 13 revealed new singlet signals at 2.80 ppm and at 2.30 ppm corresponding to 2CH₃ groups. The IR spectrum of compound 17 showed new absorption bands at 1325, 1148 cm⁻¹ corresponding to O=S=O group. The IR spectrum of compound 18 showed the absence of absorption bands corresponding to protons attached to SP³ carbons while exhibit new absorption bands at 3449, 3208, 3160 cm⁻¹ corresponding to NH₂, NH groups. The ¹H-NMR spectrum of compound 18 showed the absence of the signal corresponding to SCH₃ group while revealed new singlet signals at 11.80 ppm and at 4.30 ppm corresponding to NH and NH₂ groups, respectively. Moreover, the mass spectrum of compound 18 gave m/z250 $[M^+]$ (I_{rel}100%) which corresponds to the molecular weight of the molecular formula C₁₃H₁₀N₆ of the assigned structure.

2-Amino-6-hydrazino-4-phenylpyridine-3,5-dicarbonitrile 20 was yielded by treating compound 17 with hydrazine hydrate at room temperature, which in turn underwent intermolecular cyclization into compound 18. Also compound 18 was synthesized directly in one step by heating compound 17 with hydrazine hydrate in ethanol (Scheme 4).

In ethanol and TEA as a catalyst, compound 17 was heated with phenyl hydrazine, urea, thiourea or guanidine hydrochloride giving 6-amino-3-imino-2,4-diphenyl-2,3dihydro-1H-pyrazolo[3,4-b]pyridi-ne-5-carbonitrile 21, 1-(6-amino-3,5-dicyano-4-phenyl-pyridin-2-yl)urea 22, 1-(6amino-3,5-dicyano-4-phenylpyridin-2-yl)thiourea 23 or 1-(6-amino-3,5-dicyano-4-phenylpyridin-2-yl)guanidine 24, respectively (Scheme 4).

The IR spectrum of compound 20 showed the absence of absorption bands corresponding to SO₂ group

while exhibit new absorption bands at 3470-3230 cm⁻¹ corresponding to NH₂, NH groups. The ¹H-NMR spectrum of compound 20 showed the absence of the signal corresponding to CH₃ group. The IR spectra of compounds 21-24 showed the absence of absorption bands corresponding to SO₂ group while exhibit new absorption bands at $3466 - 3180 \text{ cm}^{-1}$ corresponding to NH₂, NH groups. The ¹H-NMR spectra of compounds **21-24** showed the absence of the signal corresponding to CH₃ group.



Scheme 4

3 Biological activity predicted by PASS

The biological activity spectra of new compounds 2-24 were obtained by PASS software. The predictions were carried out based on analysis of training set containing about 46,000 drugs and biologically active compounds. This set consider as reference compounds for known chemical compounds as well as different biological activities. It estimates the probability of the molecule to be active (Pa) and inactive (Pi) for each type of activity from the biological activity spectrum. Interpretation of prediction results is based on consideration of Pa values [22,24].

1. Pa > 0.7: the chance of finding activity experimentally is high; in many cases the compound may be a close analogue of known pharmaceutical agents.

2. 0.5 < Pa < 0.7: the chance of finding activity

experimentally is less; the compound is not so similar to known pharmaceutical agents.

3. Pa < 0.5: the chance of finding activity experimentally is even less; the compound has only a low similarity to the compounds from the training set.

Percent activity (Pa) and inactivity (Pi) of new compounds, which have Pa more than 0.700, represented in table 1.

According to these data the most frequently predicted types of biological activities are Atherosclerosis treatment, Antineoplastic and DNA intercalator. we got a very important targets for compound **17** that can be confirmed with experiments especially the target of Antiarthritic which has high probability at (Pa=0,940) and Atherosclerosis treatment at (Pa= 0.918). Whereas, compound 18 is expected to exhibit good Protein kinase inhibitor (Pa=0,944) and Signal transduction pathways inhibitor (Pa=0,943).

Compound No.	Activities	Pa	Pi
	Adenosine A2b receptor agonist	0,896	0,000
	Atherosclerosis treatment	0,896	0,003
	Adenosine A1 receptor agonist	0,713	0,002
2	Antidiabetic	0,706	0,006
	Antihypertensive	0,705	0,005
4	Heart failure treatment	0,714	0,004
8	Atherosclerosis treatment	0,765	0,004
	Heart failure treatment	0,733	0,004
11	DNA intercalator	0,730	0,003
12	DNA intercalator	0,712	0,003
	Heart failure treatment	0,784	0,004
13	Atherosclerosis treatment	0,743	0,004
	Antihypertensive	0,710	0,005
	Atherosclerosis treatment	0,828	0,004
14	Centromere associated protein	0,828	0,004
	inhibitor	0,817	0,004
	Heart failure treatment	0,803	0,004
17	Antiarthritic	0,940	0,004
	Atherosclerosis treatment	0,800	0,004
	Adenosine A2b receptor agonist	0,705	0,000
	Protein kinase inhibitor	0,944	0,004
18	Signal transduction pathways	0,943	0.004
	inhibitor	0,722	0,005
	Tyrosine kinase inhibitor	0,723	0,007
	Histidine kinase inhibitor	0,704	0,025
	Antineoplastic		
20	Beta-Lysine 5,6-aminomutase	0,867	0,000
	inhibitor	0,845	0,001
	CDK9/cyclin T1 inhibitor	0,798	0,012
	Glucose oxidase inhibitor	0,718	0,003
	Antineoplastic (brain cancer)		
22	Alopecia treatment	0,702	0,006
23	Antineoplastic (melanoma)	0,733	0,004
24	CDP-glycerol	0.070	0.014
	glycerophosphotransferase	0,868	0,016
	inhibitor	0,737	0,005
L	Alopecia treatment		

4 Conclusion

This study illustrates that 2-amino-6-(methylthio)-4phenylpyridine3,5-dicarbonitrile(**2**) is a convenient starting material for the synthesis of new series of fused pyridine derivatives. Due to the availability of the starting materials, the simplicity of the procedures, and the comparatively reasonable yields of the products, this synthetic approach might be valuable for the synthesis of such ring systems. Accompanied with predictions of the activity spectra of some selected compounds using PASS INET.at Pa > 70%, showing high probability of Atherosclerosis treatment, Antineoplastic, DNA intercalator, Protein kinase inhibitor and Signal transduction pathways inhibitor.

5 Experimental

All melting points are uncorrected and were recorded on Melt-Temp II melting point apparatus. IR spectra were measured as KBr pellets on a Shimadzu DR-8001 spectrometer. ¹H-NMR spectra were recorded in deuterated chloroform or dimethyl sulfoxide at 60 MHz on a Varian EM 360L and also at 200 MHz on a Varian Gemini NMR spectrometer using tetramethylsilane as an internal reference. Mass spectra were performed on a Shimadzu GCMS-QP 1000 mass spectrometer at 70 ev. The elemental analyses were carried out on a Perkin-Elmer 240C. All compounds were checked for their purity on TLC plates.

2-amino-6-(methylthio)-4-phenylpyridine-3,5dicarbonitrile (2):

To a solution of compound **1** (0.005 mol, 1.26 g) in sodium hydroxide (0.5 g in 20 ml H₂O), dimethyl sulphate (0.005 mol, 0.47 ml) was added drop wise with stirring. The stirring was continued for 2 h. The solid product was filtered off, crystallized from dioxaneand dried in the air ,1.14 g(86%), mp305°C; IR: 3323, 3217 (NH₂); 3069 (CH_{arom}.); 2986 (SP3 C-H.); 2219 (2CN). cm⁻¹; ¹H-NMR: 7.60(s, 2H, NH₂); 7.30 – 7.00 (m, 5H, arom.); 2.50 (s, 3H, CH₃).; Anal. Calcd. for C₁₄H₁₀N₄S:C, 63.14 , H, 3.78; N, 21.04; S, 12.04. Found: C, 63.10; H, 3.64; N, 21.13; S, 11.92.

Synthesis of compounds 3-12: General procedure:

An equimolar mixture of compound 2 (0.001 mol, 0.266 g) and the appropriate halo compound, diethyl malonate, ethyl cyanoacetate, phenacyl bromide or 2-chloroacetamide in dioxane (20 ml) was treated with anhydrous potassium carbonate (3 g) and a catalytic amount of tetrabutylammonium bromide. The reaction mixture was stirred for a period of time, filtered off and the solvent was evaporated in vacuo. The resulting solid was crystallized from ethanol.

Ethyl 4-amino-6-cyano-2-hydroxy-7-(methylthio)-5phenyl-1,8-naphthyridine-3-carboxylate (3):

Yield: 40%, mp271°C; IR: 3475 (OH); 3324, 3215 (NH₂);

3056 (CH_{arom}.); 2954 (SP³ C-H.); 2211 (CN); 1734 (C=O).cm⁻¹; ¹H nmr: 7.7 – 7.0 (m, 5H, arom.); 6.4 (s, 2H, NH₂); 4.2 (s, 1H, OH); 4.0 – 3.8 (q, 2H, CH₂ ester); 2.5 (s, 3H, CH₃S); 1.2–1.0 (t, 3H, CH₃ ester).; Anal. Calcd. for $C_{19}H_{16}N_4O_3S$: C, 59.99; H, 4.24; N, 14.73; S, 8.43. Found: C, 60.06; H, 4.35; N, 14.65; S, 8.32.

4-amino-2-hydroxy-7-(methylthio)-5-phenyl-1,8naphthyridine-3,6-dicarbonitrile (4):

Yield: 64%, mp265°C; IR: 3396 (OH); 3324, 3215 (NH₂); 3050 (CH_{arom}.); 2959 (SP³ C-H); 2198 (2CN).cm⁻¹; ¹H-NMR : 7.50–7.00 (m, 5H, arom.); 6.30 (s, 2H, NH₂); 4.00 (s, 1H, OH); 2.50 (s, 3H, CH₃).; Anal. Calcd. for $C_17H_{11}N_5OS$: C, 61.25; H, 3.33; N, 21.01; S, 9.62. Found: C, 61.38; H, 3.21; N, 21.10; S, 9.55.

3-amino-2-benzoyl-6-(methylthio)-4-phenyl-1Hpyrrolo[2,3-b]pyridine-5-carbonitrile (5):

Yield: 70%, mp132°C; IR: 3418, 3360, 3240 (NH₂, NH); 3060 (CH_{arom.}); 2926 (SP³ C-H.); 2214 (CN); 1680 (C=O). cm⁻¹; ¹H-NMR: 7.50–6.70(m, 13H, arom. + NH₂ + NH); 2.40 (s, 3H, CH₃).; Anal. Calcd. for $C_{22}H_{16}N_4OS$: C, 68.73; H, 4.19; N, 14.57; S, 8.34. Found: C, 68.66; H, 4.11; N, 14.66; S, 8.23.

3-amino-5-cyano-6-(methylthio)-4-phenyl-1Hpyrrolo[2,3-b]-pyridine-2-carboxamide (6):

Yield: 60%, mp230°C; IR: 3454, 3323, 3213 (2NH₂, NH); 3060 (CHarom.); 2931 (SP³ C-H); 2209 (CN); 1691 (C=O).cm⁻¹; ¹H-NMR: 9.90 (s, 1H, NH); 7.50 – 7.10 (m, 7H, arom. + NH₂); 6.20 (s, 2H, CONH₂); 2.50 (s, 3H, CH³).; Anal. Calcd. for $C_{16}H_{13}N_5OS$: C, 59.43; H, 4.05; N, 21.66; S, 9.92. Found: C, 59.34; H, 3.97; N, 21.62; S, 9.82.

ethyl 2-(3-amino-5-cyano-2-ethyloxycarbonyl-6methylsulfanyl-4-phenyl-1H-pyrrolo[2,3-b]pyridin-1yl)acetate (7):

Yield: 62%, mp146°C; IR: 3464, 3338 (NH₂); 3047 (CHarom.); 2989, 2933 (SP³ C-H.); 2213 (CN); 1750 (C=Oester).cm-1; ¹H-NMR: 7.40 – 6.90 (m, 5H, arom.); 4.90 (s, 2H, N–CH₂); 4.50 (s, 2H, NH₂); 4.10 – 3.70 (q, 4H, 2CH₂ ester); 2.40 (s, 3H, SCH₃); 1.40 - 1.00 (t, 6H, 2CH₃ ester).; Anal. Calcd. for C₂₂H₂₂N₄O₄S: C, 60.26; H, 5.06; N, 12.78; S, 7.31. Found: C, 60.18; H, 5.11; N, 12.86; S, 7.39.

Ethyl 2-(5-cyano-2-ethyloxycarbonyl-6-methylsulfanyl-4-phenyl-1H-pyrrolo[2,3-b]pyridin-3ylamino)- acetate (8):

Yield: 85%, mp170 °C; IR: 3463, 3329 (2NH); 3050 (CHarom.); 2988, 2933 (SP³ C-H); 2216 (CN); 1756 (C=O_{ester}).cm-1; ¹H-NMR: 7.50–7.20 (m, 6H, arom. + NH); 5.10 (s, 2H, N–CH₂); 4.60 (s, 1H, NH); 4.30 - 3.90 (q, 4H, 2CH₂ ester); 2.50 (s, 3H, SCH₃); 1.50 – 1.10 (t, 6H, 2CH₃ ester).; Anal. Calcd. for C₂₂H₂₂N₄O₄S: C, 60.26; H, 5.06; N, 12.78; S, 7.31. Found: C, 60.21; H, 5.01; N, 12.71; S, 7.25.

6-(methylthio)-8-phenyl-3,4-dihydro-2H-pyrido-[1,2-

a]pyrimidine-7,9-dicarbonitrile (9):

Yield: 76%, mp217°C; IR: 3050 (CH-arom.); 2947 (SP³ C-H); 2211 (2CN).cm⁻¹; ¹H-NMR: 7.40-7.00 (m, 5H, arom.); 4.40–4.00 (t, 4H, 2CH₂–N); 2.50 (s, 3H, CH₃); 2.50 – 2.20 (m, 2H, CH₂).; Anal. Calcd. for $C_{17}H_{14}N_4S$: C, 66.64; H, 4.61; N, 18.29; S, 10.47. Found: C, 66.51; H, 4.49; N, 18.21; S, 10.55.

7-(methylthio)-9-phenyl-2,3,4,5-tetrahydropyrido-[1,2-a][1,3]-diazepine-8,10-dicarbonitrile (10):

Yield: 96%, mp182 °C; IR: 3056 (CHarom.); 2970 (SP³ C-H.); 2205 (2CN).cm⁻¹; ¹H-NMR: 7.50-7.00 (m, 5H, arom.); 3.90 – 3.40 (t, 4H, 2CH₂-N); 2.50 (s, 3H, CH₃); 2.20–1.60 (m, 4H, 2CH₂).; Anal. Calcd. for $C_{18}H_{16}N_4S$: C, 67.47; H, 5.03; N, 17.49; S, 10.01. Found: C, 67.39; H, 5.12; N, 17.33; S, 10.08.

4-methylsulfanyl-6,11-dioxo-2-phenyl-6,11-dihydronaphtho-[2',3':4,5]imidazo[1,2-a]pyridine-1,3dicarbonitrile (11):

Yield: 77%, mp310°C; IR: 3059 (CHarom.); 2928 (SP³ C-H.); 2204 (2CN); 1673 (2C=O).cm-1; ¹H-NMR: 7.80 -7.20 (m, 9H, arom.); 2.40 (s, 3H, CH₃).; Anal. Calcd .for $C_{24}H_{12}N_4O_2S$: C, 68.56; H, 2.88; N, 13.33; S, 7.63. Found: C, 68.45; H, 2.95; N, 13.24; S, 7.52.

7,8-dihydroxy-1-(methylthio)-6,9-dioxo-3-phenyl-6,9dihydropyrido[1,2-a]benzimidazole-2,4-dicarbonitrile (12):

Yield: 73 %, mp280°C; IR: 3736, 3444 (2OH); 3062 (CHarom.); 2932 (SP³ C-H); 2212 (2CN); 1644 (2C=O).cm⁻¹; ¹H-NMR: 7.50–7.00 (m, 5H, arom.); 3.80 (s, 2H, 2OH); 2.50 (s, 3H, CH₃).; Anal. Calcd. for $C_{20}H_{10}N_4O_4S$: C, 59.70; H, 2.50; N, 13.92; S, 7.97. Found: C, 59.62; H, 2.63; N, 14.01; S, 7.83.

6-cyano-2-methyl-7-(methylthio)-5-phenylpyrido-[2,3d]pyrimidin-4-yl acetate (13):

A solution of compound**2** (0.001 mol, 0.266 g) in acetic anhydride (15 ml) was heated under reflux for 4 h and then allowed to cool to room temperature. The reaction mixture was poured onto ice cold water. The obtained solid product was filtered, washed with water and crystallized from ethanol, 0.29 g(83%), mp175°C; IR: 3016 (CHarom.); 2934 (SP³ C-H.); 2223 (CN); 1733 (C=O_{ester}). cm⁻¹; ¹H-NMR: 7.40–7.10(m, 5H, arom.); 2.80 (s, 3H, CH₃–C=N); 2.50 (s, 3H, CH₃CO); 2.30 (s, 3H, CH₃S).; Anal. Calcd. for C₁₈H₁₄N₄O₂S:C, 61.70, H, 4.03; N, 15.99; S, 9.15. Found: C, 61.60; H, 4.00; N, 16.07; S, 9.09.

2-(methylthio)-4-phenyl-6-(1H-pyrrol-1-yl)pyridine-3,5-dicarbonitrile (14):

An equimolar ratio of compound 2 (0.001 mol, 0.266 g) and 2,5-dimethoxytetrahydrofuran (0.001 mol, 0.13 ml) in glacial acetic acid (10 ml), was heated under reflux for 4 h

and left to cool. The precipitated crystals was collected by filtration and crystallized from ethanol, 0.20 g(64%), mp198°C; IR: 3070 (CHarom.); 2930 (SP³ C-H); 2223 (2CN). cm⁻¹; ¹H-NMR: 7.60–7.40 (d, 2H, =CH-N); 7.30 – 7.10 (m, 5H, arom.); 6.30–6.10 (t, 2H, 2 =CH-C); 2.60 (s, 3H, CH₃).; Anal. Calcd. for $C_{18}H_{12}N_4S:C$, 68.33, H, 3.82; N, 17.71; S, 10.13. Found: C, 68.21; H, 3.74; N, 17.61; S, 10.22.

4-imino-7-(methylthio)-3,5-diphenyl-2-thioxo-1,2,3,4tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile (15):

An equimolarmixture of compound **2** (0.001 mol, 0.266 g) and phenylisothiocyanate (0.001 mol, 0.12 ml) in dioxane(20 ml) was treated with anhydrous potassium carbonate (3 g) and a catalytic amount of tetrabutylammonium bromide. The reaction mixture was stirred for 4 h at 60-70 °C The precipitated crystals was collected by filtration and crystallized from ethanol, 0.18 g(45 %), mp160°C; IR: 3439 (NH); 3330 (NH); 3062 (CHarom.); 2935(SP³ C-H); 2213(CN); 1533 (C=S). cm⁻¹; ¹H-NMR: 7.30 – 6.90 (m, 10H, arom.); 6.20 (s, 1H, NH); 4.00 (s, 1H, NH); 2.50 (s, 3H, CH₃).; Anal. Calcd. for C₂₁H₁₅N₅S₂:C, 62.82, H, 3.77; N, 17.44; S, 15.97. Found: C, 62.95; H, 3.86; N, 17.37; S, 16.00.

4-chloro-7-(methylthio)-5-phenylpyrido[2,3-d]-[1,2,3]triazine-6-carbonitrile (16):

To a chilled solution of compound**2**(0.001 mol, 0.266 g) in a mixture of acetic acid (10 ml) and concentrated hydrochloric acid (7 ml), a sodium nitrite solution 10% (1 ml) was added with stirring during 5 min. The stirring was continued at 5°C for 3 h. The formed precipitate was collected by filtration and crystallized from ethanol, 0.24 g (78%), mp192°C; IR: 3054 (CHarom.); 2929(SP³ C-H); 2211 (CN). cm⁻¹; ¹H-NMR: 7.40–7.10 (m, 5H, arom.); 2.50 (s, 3H, CH₃).; Anal. Calcd. for C₁₄H₈ClN₅S:C, 53.59, H, 2.57; N, 22.32; S, 10.22. Found: C, 53.51; H, 2.45; N, 22.43; S, 10.29.

2-amino-6-(methylsulfonyl)-4-phenylpyridine-3,5dicarbonitrile (17):

To a solution of compound 2(0.001 mol, 0.266 g) in glacial acetic acid (30 ml), potassium permanganate solution (0.001 mol, 0.158 g in 1 ml H₂O) was added during 5 min. The stirring was continued at r.t for 3 h. The reaction mixture was filtrated. The filtrate poured onto water and the resulting solid was crystallized from ethanol, 0.17 g (58%), mp240°C; IR: 3331, 3223 (NH₂); 3014 (CHarom.); 2924 (SP³ C-H); 2224 (2CN); 1325, 1148 (SO₂). cm-1; ¹H-NMR: 7.90 (s, 2H, NH₂); 7.40–7.10 (m, 5H, arom.); 3.20 (s, 3H, CH₃).; Anal. Calcd. for C₁₄H₁₀N₄O₂S:C, 56.37, H, 3.38; N, 18.78; S, 10.75. Found: C, 56.50; H, 3.21; N, 18.66; S, 10.62.

3,6-diamino-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5carbonitrile (18):

Method A:

A mixture of compound 2(0.001 mol, 0.266 g) and hydrazine hydrate (5 ml) was heated under reflux for about 9 h until the odor of CH3SH ceased and then allowed to cool to room temperature. The mixture triturated with ethanol (10 ml). The solid product was filtered and crystallized from ethanol.

Method B:

A mixture of compound 17(0.001 mol, 0.298 g) and hydrazine hydrate (0.1 ml) in ethanol (20 ml) was refluxed for 2 h. The product that formed by cooling was collected by filtration and crystallized from ethanol.

Method C:

To a solution of compound 20 (0.001 mol, 0.25 g) in ethanol (20 ml), TEA (2 drops) was added. The reaction mixture was refluxed for 2 h. The product that formed after cooling was collected by filtration and crystallized from ethanol.

Yield: 65%, mp282°C; IR: 3449, 3338, 3208, 3160 (2NH₂, NH); 3055 (CHarom.); 2205 (CN).cm⁻¹; ¹H-NMR: 11.80 (s, 1H, NH); 7.80–7.20 (m, 5H, arom.); 6.80 (s, 2H, NH₂); 4.30 (s, 2H, NH₂).; Anal. Calcd. for $C_{13}H_{10}N_6$: C, 62.39; H, 4.03; N, 33.58. Found: C, 62.28; H, 3.92; N, 33.66.

2-methyl-7-methylsulfanyl-5-phenyl-4-(1-thioxoethylimino)-3,4-dihydropyrido[2,3-d]pyrimidin-6-yl cyanide (19):

A mixture of compound **2** (0.001 mol, 0.266 g) and thioacetamide (0.001 mol, 0.075 g) in trifluoroacetic acid (5 ml) was refluxed for 24 h. The mixture was left to cool, was poured onto ice cold water. The obtained solid product was filtered, washed with water and crystallized from dioxane, 0.24 g (65%), mp289°C; IR: 3322 (NH); 3063 (CHarom.); 2930 (SP³ C-H); 2216 (CN); 1540 (C=S). cm⁻¹; ¹H-NMR: 7.40–7.10 (m, 6H, arom. + NH); 2.60 (s, 3H, CH₃); 2.50 (s, 6H, 2CH₃).; Anal. Calcd. for C₁₈H₁₅N₅S₂:C, 59.15, H, 4.14; N, 19.16; S, 17.55. Found: C, 59.22; H, 4.11; N, 19.09; S, 17.46.

2-amino-6-hydrazino-4-phenylpyridine-3,5-dicarbonitrile (20):

A mixture of compound17 (0.001 mol, 0.298 g) and hydrazine hydrate (0.1 ml) in ethanol (20 ml) was stirred for 2 h at r.t. The product that formed was collected by filtration and crystallized from ethanol, 0.12 g (48%),mp225°C; IR: 3470, 3332, 3230 (2NH₂, NH); 3050 (CHarom.); 2203 (2CN). cm⁻¹; ¹H-NMR: 7.60 – 7.00 (m, 5H, arom.); 6.90 – 6.30 (br, 1H, NH); 4.00 – 3.20 (br, 4H, 2NH₂).; Anal. Calcd. for $C_{13}H_{10}N_6$:C, 62.39, H, 4.03; N, 33.58. Found: C, 62.48; H, 4.10; N, 33.27.

Synthesis of compounds 21–24:

General procedure:

To a mixture of compound 17(0.001 mol, 0.298 g) and an equiomolar ratio of phenyl hydrazine, urea,

thiourea or guanidine hydrochloride in ethanol (20 ml), TEA (0.15 ml) was added. The reaction mixture was heated under reflux for 4 h, allowed to cool and concentrated. The product that formed was collected by filtration and crystallized from ethanol.

6-amino-3-imino-2,4-diphenyl-2,3-dihydro-1Hpyrazolo[3,4-b]-pyridine-5-carbonitrile (21):

Yield: 45%, mp220°C; IR: 3466, 3319, 3206, 3180 (NH₂, 2NH); 3070 (CHarom.); 2219 (CN).cm⁻¹; ¹H-NMR: 7.80 – 7.00 (m, 12H, arom. + NH₂); 6.20 (s, 1H, NH); 4.80 (s, 1H, NH).; Anal. Calcd. for $C_{19}H_{14}N_6$: C, 69.92; H, 4.32; N, 25.75. Found: C, 7.03; H, 4.21; N, 25.83.

1-(6-amino-3,5-dicyano-4-phenylpyridin-2-yl)urea(22):

Yield: 42%, mp185°C; IR: 3460, 3323, 3206 (2NH₂, NH); 3053 (CHarom.); 2207 (2CN); 1642 (C=O).cm-1; ¹H-NMR: 7.40 – 6.90 (m, 6H, arom. + NH); 4.20 (s, 4H, 2NH₂).; Anal. Calcd. for $C_{14}H_{10}N_6O$: C, 60.43; H, 3.62; N, 30.20. Found: C, 60.35; H, 3.56; N, 30.27.

1-(6-amino-3,5-dicyano-4-phenylpyridin-2-yl)thiourea (23):

Yield: 40%, mp295°C; IR: 3454, 3322, 3211 (2NH₂, NH); 3060 (CHarom.); 2216 (2CN); 1557 (C=S).cm-1; ¹H-NMR: 7.40–6.90 (m, 6H, arom. + NH); 3.80 (s, 4H, 2NH₂).; Anal. Calcd. for $C_{14}H_{10}N_6S$: C, 57.13; H, 3.42; N, 28.55; S, 10.89. Found: C, 57.21; H, 3.32; N, 28.43; S, 10.75.

1-(6-amino-3,5-dicyano-4-phenylpyridin-2-yl)guanidine (24):

Yield: 75%, mp222°C; IR: 3457, 3323, 3218 (2NH₂, 2NH); 3055 (CHarom.); 2215 (2CN).cm⁻¹; ¹H-NMR: 7.40 – 6.90 (m, 6H, arom. + NH); 3.50 (s, 5H, 2NH₂ + NH).; Anal. Calcd. for $C_{14}H_{11}N_7$: C, 60.64; H, 4.00; N, 35.36. Found: C, 60.56; H, 3.95; N, 35.28.

References

- [1] C. Y. Hong, Y. K. Kirn, J. H. Chang, S. H. Kirn, H. Choi, D. H. Nam, Y. Z. Kim, and J. H. Kwak, *J. Med. Chem.*, **40**, 3584 (1997).
- [2] L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum, J. Antimicrob. Chemother, 45, 525 (2000).
- [3] V. Yuii, T. Shigeru, I. Satochi, Y. Teruaki, J. Pharm. Pharmacol, 45, 1077 (1993).
- [4] T. Kenichi, S. Takehiko, S. Junko and H. Takeo, *Heterocycles*, 35, 915 (1993).
- [5] W. Takeo, S. Toshohide and S. Takafumi, *Eur. Pat. Appl. Ep* 562479 (1993).
- [6] K.B. Szwed, M. Lipowsica and B. Rys, Liebigs Ann Chem., 1147 (1990).
- [7] J.P. Sanchez, Tetrahedron, 46, 7693 (1990).
- [8] Almerico, A. M.; Diana, P.; Barraja, P.; Dattolo, G.; Mingoia, F.;Loi, A.G.; Scintu, F.; Milia, C.; Puddu, I.; La Colla, P. *Il Farmaco*, **53**, 33-40(1998).

- [9] Carpio, H.; Galeazzi, E.; Greenhouse, R.; Guzman, A.; Velarde, E.; Antonio, Y.; Franco, F.; Leon, A.; Perez, V.; Salas, R.; Valdes, D.; Ackrell, J.; Cho, D.; Gallegra, P.; Halpern, O.; Koehler, R.;Maddox, M.L.; Muchowski, J.M.; Prince, A.; Tegg, D.; Thurber, T.C.; VanHorn, A. R. and Wren, D. *Can. J. Chem.* **60**, 2295-2312(1982).
- [10] Dannhar, D.T.; Kiefer, G.; Kramer, W.; Maehrlein, G.; Nowe and S.;Fiebich, U. *Eur. J. Med. Chem.*, **35**, 499-510(2000).
- [11] Evans, M.A.; Smith, D.C.; Holub, J.M.; Argenti, A.; Hoff, M.;Dalglish, G.A.; Wilson, D.L.; Taylor, B.M.; Berkowitz, J.D.; Burnham, B.S.; Krumpe, K.; Gupton, J.T.; Scarlett, T.C.; Durham, R. and Hall I.H. Arch. Pharm. Med. Chem., 336, 181-190(2003).
- [12] Fahmy, H. T. Y.; Sherif Rostom, S. A. F. and Bekhit A. A. Arch. Pharm. Med. Chem., 5, 213- 222(2002).
- [13] Nasr, M. N. and Gineinah, M. M., Arch. Pharm., 335, 289-295(2002).
- [14] Tozkoparan, B.; Ertan, M.; Kelicen, P.; Demirdamar, R. *Il Farmaco*, 54, 588-593(1999).
- [15] Amr, E. A.; Ashraf, M. M.; Salwa, F. M.; Nagla, A. A. and Hammam, A. G. *Bioorgan. Med. Chem.*, **14**, 5481-5488(2006).
- [16] Kumar, N.; Singh, G. and Yadav A. K., *Heteroat. Chem.*, **12**, 52-56(2001).
- [17] Mangalagiu, G.; Ungureanu, M.; Grosu, G.; Mangalagiu, I. and Petrovanu, M., Ann. Pharm. Fr., 59, 139-140(2001).
- [18] Conti, P.; Pinto, A.; Tamborini, L.; Rizzo, V. and De Micheli, C., *Tetrahedron*, **63**, 5554-5560(2007).
- [19] Penning, D. T.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gergory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.and Isakson, P. C., J. Med. Chem., 40, 1347-1365(1997).
- [20] Hoepping, A.; Diekers, M.; Deuther-Conrad, W.; Scheunemann, M.; Fischer, S.; Hiller, A.; Wegner, F.; Steinbach, J. and Brust, P., *Bioorg. Med. Chem.*, 16, 1184-1194(2008).
- [21] Anwar, H. F. and Elnagdi, M. H., Arkivoc, (i), 198-250(2009).
- [22] http://www.pharmaexpert.ru/passonline/
- [23] Dhongade S. R., Reviews of Literature, Volume 1, Issue 1, (2013).
- [24] El-Saghier A. M. M, Ahmed E. A. and Mahmoud A. M. A., J. Pharm. Appl. Chem., 1(1), 9-19 (2015)